Tri-Iodothyronine as a Hormone Potentiator in Advanced Breast Cancer
Author Information
Author(s): B. A. Stoll
Primary Institution: Peter MacCallum Clinic, Melbourne, Australia
Hypothesis
Can tri-iodothyronine (T3) combined with oestrogen improve treatment outcomes in advanced breast cancer?
Conclusion
The study found no evidence that adding thyroid or T3 to oestrogen therapy improves outcomes in advanced breast cancer.
Supporting Evidence
- Only 3 out of 12 patients showed any regression of tumors.
- Patients who had previously responded to oestrogens did not respond to the addition of T3.
- Some patients experienced severe side effects leading to treatment discontinuation.
Takeaway
Doctors wanted to see if a thyroid hormone could help women with advanced breast cancer when other treatments weren't working, but it didn't help.
Methodology
Patients with advanced breast cancer were treated with oestrogen and either thyroid extract or T3 for up to three months.
Limitations
The small sample size and the lack of control group limit the findings.
Participant Demographics
All participants were postmenopausal women with advanced breast cancer.
Want to read the original?
Access the complete publication on the publisher's website